![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: RUNX1T1 |
Gene summary for RUNX1T1 |
![]() |
Gene information | Species | Human | Gene symbol | RUNX1T1 | Gene ID | 862 |
Gene name | RUNX1 partner transcriptional co-repressor 1 | |
Gene Alias | AML1-MTG8 | |
Cytomap | 8q21.3 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | B2R6I9 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
862 | RUNX1T1 | HTA12-15-2 | Human | Pancreas | PDAC | 4.41e-04 | 3.66e-01 | 0.2315 |
862 | RUNX1T1 | HTA12-23-1 | Human | Pancreas | PDAC | 2.91e-17 | 1.17e+00 | 0.3405 |
862 | RUNX1T1 | HTA12-25-1 | Human | Pancreas | PDAC | 1.68e-12 | 8.37e-01 | 0.313 |
862 | RUNX1T1 | HTA12-26-1 | Human | Pancreas | PDAC | 1.81e-32 | 1.15e+00 | 0.3728 |
862 | RUNX1T1 | HTA12-29-1 | Human | Pancreas | PDAC | 1.45e-57 | 1.09e+00 | 0.3722 |
862 | RUNX1T1 | HTA12-30-1 | Human | Pancreas | PDAC | 2.27e-04 | 9.49e-01 | 0.3671 |
862 | RUNX1T1 | HTA12-32-1 | Human | Pancreas | PDAC | 4.23e-05 | 9.52e-01 | 0.3624 |
862 | RUNX1T1 | ATC12 | Human | Thyroid | ATC | 6.70e-03 | 1.48e-01 | 0.34 |
862 | RUNX1T1 | ATC13 | Human | Thyroid | ATC | 1.32e-57 | 9.87e-01 | 0.34 |
862 | RUNX1T1 | ATC4 | Human | Thyroid | ATC | 1.56e-05 | 1.90e-01 | 0.34 |
862 | RUNX1T1 | ATC5 | Human | Thyroid | ATC | 1.19e-57 | 1.04e+00 | 0.34 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Stomach | WIM | ![]() |
Stomach | SIM | ![]() |
Liver | NAFLD | ![]() |
Liver | Cirrhotic | ![]() |
Liver | HCC | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004544423 | Thyroid | ATC | fat cell differentiation | 105/6293 | 229/18723 | 7.42e-05 | 5.62e-04 | 105 |
GO:004559822 | Thyroid | ATC | regulation of fat cell differentiation | 61/6293 | 139/18723 | 7.28e-03 | 2.86e-02 | 61 |
GO:0045599 | Thyroid | ATC | negative regulation of fat cell differentiation | 28/6293 | 56/18723 | 8.12e-03 | 3.13e-02 | 28 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RUNX1T1 | SNV | Missense_Mutation | novel | c.920C>A | p.Thr307Asn | p.T307N | protein_coding | tolerated(0.06) | probably_damaging(0.996) | TCGA-4H-AAAK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | CR | |
RUNX1T1 | SNV | Missense_Mutation | c.756N>C | p.Gln252His | p.Q252H | protein_coding | deleterious(0.01) | probably_damaging(0.991) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | ||
RUNX1T1 | SNV | Missense_Mutation | rs147343453 | c.1940N>T | p.Pro647Leu | p.P647L | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.992) | TCGA-AC-A8OP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
RUNX1T1 | SNV | Missense_Mutation | novel | c.1175A>T | p.His392Leu | p.H392L | protein_coding | tolerated(0.12) | benign(0.005) | TCGA-AC-A8OQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
RUNX1T1 | SNV | Missense_Mutation | rs764987407 | c.1556N>T | p.Ala519Val | p.A519V | protein_coding | deleterious(0.02) | probably_damaging(0.996) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
RUNX1T1 | SNV | Missense_Mutation | c.388N>C | p.Phe130Leu | p.F130L | protein_coding | tolerated(0.06) | benign(0.373) | TCGA-AN-A0AM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
RUNX1T1 | SNV | Missense_Mutation | c.673N>G | p.His225Asp | p.H225D | protein_coding | deleterious(0) | possibly_damaging(0.847) | TCGA-C8-A8HP-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR | ||
RUNX1T1 | SNV | Missense_Mutation | c.1030N>A | p.Gln344Lys | p.Q344K | protein_coding | tolerated(0.27) | probably_damaging(0.968) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
RUNX1T1 | SNV | Missense_Mutation | rs377029087 | c.1487N>T | p.Ala496Val | p.A496V | protein_coding | tolerated(0.2) | benign(0.005) | TCGA-E2-A14X-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
RUNX1T1 | SNV | Missense_Mutation | rs766588136 | c.775G>A | p.Ala259Thr | p.A259T | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-E9-A22D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |